Abstract The incidence rates of The incidence rates of diabetes and cancer are growing globally. It is reported that type 2 diabetes (T2D) is associated with increased risk of cancers, which suggests a synergy. There is a strong association among inflammation and cancer on diabetes, which is reflected by the high cytokine prevalence in the microenvironment. Previously our studies showed that IL-2 and IFN-γ were downregulated but IL-6 and TNFα were upregulated in diabetic mice. The levels of IL-2, IFN-γ, IL-6 and TNFα returned to baseline levels similar to that of non-diabetic mice after the treatment of CJC-1134-PC. In order to explore the benefits of CJC-1134-PC beside its glucose lowering effects, the level of pro-inflammatory cytokines has been measured and compared between vehicle and CJC-1134-PC treated BALB/c mice bearing CT26 colon tumors. All mice bearing tumors showed high IL-6 and TNF-r compared with the normal mice. Interestingly, after CJC-1134-PC treatment, IL-6 and TNFα levels decreased significantly (P < 0.05), which makes the cytokine profile close to the reported levels in normal mice. Overall, the data suggests that CJC-1134-PC plays a role in modulating inflammation, which could benefit cancer treatment in addition to achieving glycemic control. Citation Format: Xiping Liu, Sean Hong, Shijuan Wu, Zhiwen Yao, Qiang Xie. Cjc-1134-pc, a long-acting glp-1r agonist, effects in modulating pro-inflammatory cytokines in the tumor environment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1990.